How I Treat

Back to Top
The "How I Treat" series has been published by Blood for several decades and covers a wide variety of topics in malignant and classical hematology. While these articles are not considered to be formal guidelines, they are considered highly reputable sources of expert opinion. They cover topics ranging from commonly encountered hematologic conditions with a large evidence base, to very rare conditions with only case reports to guide treatment. The purpose of this page is to consolidate the links to all known published How I Treat articles. While the vast majority of these are published in Blood, there are a few exceptions.
In the first two sections (malignant hematology and classical hematology), articles are presented by condition, in reverse chronological order. In the third section, articles are gathered under "special considerations" such as pregnancy and hematologic disease. The fourth section contains miscellaneous topics that do not easily fit into the above categories. Some articles have topics that overlap sections, in which cases the link is made available in all applicable sections. Given the rapid change in evidence in many areas of hematology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
=Malignant hematology=
==Acute leukemias==
===Mixed-phenotype acute leukemia (MPAL)===
*2015: Wolach & Stone. How I treat mixed-phenotype acute leukemia EuroPMC
==Myeloid neoplasms==
===Acute myeloid leukemia (AML)===
*2024: Thol et al. How I treat refractory and relapsed acute myeloid leukemia EuroPMC
**2020: DeWolf & Tallman. How I treat relapsed or refractory AML EuroPMC
*2023: Biederstädt & Rezvani. How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy EuroPMC
*2023: El Chaer et al. How I treat AML incorporating the updated classifications and guidelines EuroPMC
*2021: Falini et al. How I diagnose and treat NPM1-mutated AML EuroPMC
*2021: Rubnitz & Kaspers. How I treat pediatric acute myeloid leukemia EuroPMC
*2020: DiNardo & Wei. How I treat acute myeloid leukemia in the era of new drugs EuroPMC
*2016: Ofran et al. How I treat acute myeloid leukemia presenting with preexisting comorbidities EuroPMC
*2016: Peffault de Latour & Soulier. How I treat MDS and AML in Fanconi anemia EuroPMC
*2016: Pratz & Levis. How I treat FLT3-mutated AML EuroPMC
*2015: Röllig & Ehninger. How I treat hyperleukocytosis in acute myeloid leukemia EuroPMC
*2014: Ossenkoppele & Löwenberg. How I treat the older patient with acute myeloid leukemia EuroPMC
**2000: Estey. How I treat older patients with AML EuroPMC
*2011: Bakst et al. How I treat extramedullary acute myeloid leukemia EuroPMC
===Acute promyelocytic leukemia (APL)===
*2014: Sanz & Motesinos. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia EuroPMC
*2009: Tallman & Altman. How I treat acute promyelocytic leukemia EuroPMC
===Blastic plasmacytoid dendritic cell neoplasm (BPDCN)===
*2025: Kharfan-Dabaja et al. How I treat blastic plasmacytoid dendritic cell neoplasm EuroPMC
===Chronic myeloid leukemia (CML)===
*2022: Berman. How I treat chronic-phase chronic myelogenous leukemia
*2019: Hijiya & Suttorp. How I treat chronic myeloid leukemia in children and adolescents EuroPMC
*2016: Gotlib. How I treat atypical chronic myeloid leukemia EuroPMC
*2012: Cortes & Kantarjian. How I treat newly diagnosed chronic phase CML EuroPMC
*2009: Radich. How I monitor residual disease in chronic myeloid leukemia EuroPMC
===Chronic myelomonocytic leukemia (CMML)===
*2017: Solary & Itzykson. How I treat chronic myelomonocytic leukemia EuroPMC
===Hypereosinophilic syndrome (HES)===
*2015: Klion. How I treat hypereosinophilic syndromes EuroPMC
===Myelodysplastic syndrome (MDS)===
*2025: Leitch & Buckstein How I treat iron overload in adult MDS EuroPMC
*2024: Mina et al. How I reduce and treat posttransplant relapse of MDS EuroPMC
*2019: Santini. How I treat MDS after hypomethylating agent failure
*2018: Locatelli & Strahm. How I treat myelodysplastic syndromes of childhood EuroPMC
*2018: Steensma. How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes EuroPMC
*2016: Peffault de Latour & Soulier. How I treat MDS and AML in Fanconi anemia EuroPMC
*2013: Sekeres & Cutler. How we treat higher-risk myelodysplastic syndromes EuroPMC
*2013: Fenaux & Adès. How we treat lower-risk myelodysplastic syndromes
===Myeloproliferative neoplasms (MPNs)===
*2024: Robinson et al. How I treat myeloproliferative neoplasms in pregnancy EuroPMC
*2018: Odenike. How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms EuroPMC
====Essential thrombocythemia (ET)====
*2016: Rumi & Cazzola. How I treat essential thrombocythemia EuroPMC
====Myelofibrosis (MF)====
*2023: Kröger et al. How I treat transplant-eligible patients with myelofibrosis EuroPMC
*2018: Pardanani & Tefferi. How I treat myelofibrosis after failure of JAK inhibitors EuroPMC
*2011: Tefferi. How I treat myelofibrosis EuroPMC
====Polycythemia vera (PV)====
*2019: Spivak. How I treat polycythemia vera EuroPMC
*2014: Vannucchi. How I treat polycythemia vera EuroPMC
===Systemic mastocytosis===
*2013: Pardanani. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage) EuroPMC
==Lymphoid neoplasms==
===Acute lymphoblastic leukemia (ALL)===
*2025: Bartram et al. How I treat infant acute lymphoblastic leukemia EuroPMC
*2025: Chiaretti & Foà. How I treat adult Ph+ ALL EuroPMC
*2025: Gökbuget & Steffen. How I treat older patients with Ph/BCR-ABL-negative acute lymphoblastic leukemia EuroPMC
**2013: Gökbuget. How I treat older patients with ALL EuroPMC
*2025: Lamble et al. How I treat postimmunotherapy relapsed B-ALL EuroPMC
*2025: Summers et al. How I treat ETP-ALL in children EuroPMC
*2025: Tran & Tasian. How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults EuroPMC
*2024: Muffly et al. How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL EuroPMC
*2023: Kopmar & Cassaday. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia EuroPMC
*2023: Myers et al. How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL EuroPMC
*2023: Si Lim et al. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults EuroPMC
*2020: Aldoss & Douer. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia EuroPMC
*2020: Aldoss & Forman. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy EuroPMC
*2020: Hunger & Raetz. How I treat relapsed acute lymphoblastic leukemia in the pediatric population EuroPMC
*2020: Teachey & O'Connor How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children EuroPMC
*2019: Ravandi. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia EuroPMC
*2015: Curran & Stock. How I treat acute lymphoblastic leukemia in older adolescents and young adults EuroPMC
*2015: Frey & Luger. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia EuroPMC
*2015: Litzow & Ferrando. How I treat T-cell acute lymphoblastic leukemia in adults EuroPMC
*2012: Locatelli et al. How I treat relapsed childhood acute lymphoblastic leukemia EuroPMC
*2007: Rowe & Goldstone. How I treat acute lymphocytic leukemia in adults EuroPMC
===Adult T-cell leukemia-lymphoma (ATLL)===
*2021: Cook & Phillips How I treat adult T-cell leukemia/lymphoma EuroPMC
===Anaplastic large cell lymphoma===
*2018: Metha-Shah et al. How I treat breast implant-associated anaplastic large cell lymphoma EuroPMC
===Burkitt lymphoma (BL)===
*2018: Gopal & Gross. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa EuroPMC
*2014: Jacobson & LaCasce. How I treat Burkitt lymphoma in adults EuroPMC
===Castleman disease===
*2022: Brandstadter & Fajgenbaum. How we manage idiopathic multicentric Castleman disease EuroPMC
*2010: Bower. How I treat HIV-associated multicentric Castleman disease EuroPMC
===Chronic lymphocytic leukemia (CLL/SLL)===
*2021: Lew et al. How I treat chronic lymphocytic leukemia after venetoclax
*2019: Stephens & Byrd. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
*2018: Brown. How I treat CLL patients with ibrutinib EuroPMC
*2018: Gribben. How and when I do allogeneic transplant in CLL EuroPMC
*2017: Woyach. How I manage ibrutinib-refractory chronic lymphocytic leukemia EuroPMC
*2009: Gribben. How I treat CLL up front EuroPMC
===Classical Hodgkin lymphoma (cHL)===
*2021: Epperla & Herrera. How I incorporate novel agents into the treatment of classical Hodgkin lymphoma
*2015: Alinari & Blum. How I treat relapsed classical Hodgkin lymphoma after autologous stem cell transplant EuroPMC
*2014: Uldrick & Little. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus EuroPMC
===CNS lymphoma===
*2023: Alderuccio et al. How I treat secondary CNS involvement by aggressive lymphomas EuroPMC
*2017: Chin & Cheah. How I treat patients with aggressive lymphoma at high risk of CNS relapse EuroPMC
*2013: Rubenstein et al. How I treat CNS lymphomas EuroPMC
===Cutaneous T-cell lymphoma (CTCL)===
*2019: Shinohara & Shustov. How I treat primary cutaneous CD30 + lymphoproliferative disorders
*2016: Whittaker et al. How I treat mycosis fungoides and Sézary syndrome EuroPMC
===Diffuse large B-cell lymphoma (DLBCL)===
*2025: Wallace et al. How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma EuroPMC
*2023: Lugtenburg & Mutsaers. How I treat older patients with DLBCL in the frontline setting EuroPMC
===Follicular lymphoma (FL)===
*2019: Casulo & Barr. How I treat early-relapsing follicular lymphoma EuroPMC
===High-grade B-cell lymphoma (HGBL)===
*2017: Friedberg. How I treat double-hit lymphoma EuroPMC
===HIV-associated lymphoma===
*2014: Uldrick & Little. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus EuroPMC
*2012: Dunleavy & Wilson. How I treat HIV-associated lymphoma EuroPMC
*2010: Bower. How I treat HIV-associated multicentric Castleman disease EuroPMC
===Large granular lymphocytic leukemia (T-LGL)===
*2011: Lamy & Loughran. How I treat LGL leukemia EuroPMC
===Mantle cell lymphoma (MCL)===
*2009: Ghielmini & Zucca. How I treat mantle cell lymphoma EuroPMC
===NK- and T-cell lymphoma (NKTCL)===
*2013: Tse & Kwong. How I treat NK/T-cell lymphomas EuroPMC
===Nodular lymphocyte-predominant Hodgkin lymphoma (NLP-HL)===
*2020: Eichenauer & Engert. How I treat nodular lymphocyte-predominant Hodgkin Lymphoma
*2013: Advani & Hoppe. How I treat nodular lymphocyte predominant Hodgkin lymphoma EuroPMC
===Peripheral T-cell lymphoma (PTCL)===
*2014: Moskowitz et al. How I treat the peripheral T-cell lymphomas EuroPMC
===Post-transplant lymphoproliferative disorder (PTLD)===
*2023: Amengual & Pro. How I treat posttransplant lymphoproliferative disorder EuroPMC
*2015: Dierickx et al. How I treat posttransplant lymphoproliferative disorders EuroPMC
===Primary mediastinal B-cell lymphoma (PMBCL)===
*2018: Giulino-Roth. How I treat primary mediastinal B-cell lymphoma EuroPMC
===Prolymphocytic leukemia (T-PLL)===
*2012: Dearden. How I treat prolymphocytic leukemia EuroPMC
===Splenic lymphoma===
*2011: Iannitto & Tripodo. How I diagnose and treat splenic lymphomas EuroPMC
===Transformed lymphoma===
*2014: Parikh et al. How we treat Richter syndrome EuroPMC
===Waldenström macroglobulinemia (WM)===
*2024: Treon et al. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia EuroPMC
*2019: Dimopoulos & Kastritis. How I treat Waldenström macroglobulinemia EuroPMC
*2015: Treon. How I treat Waldenström macroglobulinemia EuroPMC
==Plasma cell dyscrasias==
===Light-chain (AL) amyloidosis===
*2022: Palladini & Merlini. How I treat AL amyloidosis
*2012: Leung et al. How I treat amyloidosis: the importance of accurate diagnosis and amyloid typing EuroPMC
===MGUS===
*2013: Fermand et al. How I treat monoclonal gammopathy of renal significance (MGRS) EuroPMC
===Multiple myeloma (MM)===
*2024: Facon et al. How I treat multiple myeloma in geriatric patients EuroPMC
**2010: Mehta et al. How I treat elderly patients with myeloma EuroPMC
*2023: van de Donk. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells
*2022: Kastritis et al. How I treat relapsed multiple myeloma
**2014: Bladé et al. How I treat relapsed myeloma EuroPMC
*2022: Perrot. How I treat frontline transplantation-eligible multiple myeloma EuroPMC
*2022: Vaxman & Gertz. How I approach smoldering multiple myeloma
*2022: Zamagni et al. How I treat high-risk multiple myeloma
**2015: Lonial et al. How I treat high-risk myeloma EuroPMC
*2017: Harousseau & Attal. How I treat first relapse of myeloma EuroPMC
*2017: Moreau. How I treat myeloma with new agents EuroPMC
*2015: Larocca & Palumbo. How I treat fragile myeloma patients EuroPMC
*2015: Touzeau & Moreau. How I treat extramedullary myeloma EuroPMC
*2014: Gertz & Dingli. How we manage autologous stem cell transplantation for patients with multiple myeloma EuroPMC
*2009: Stewart et al. How I treat multiple myeloma in younger patients EuroPMC
===Plasma cell leukemia (PCL)===
*2012: van de Donk et al. How I treat plasma cell leukemia EuroPMC
===Smoldering multiple myeloma (SMM)===
*2014: Ghobrial & Landgren. How I treat smoldering multiple myeloma EuroPMC
==Histiocytic disorders==
===Hemophagocytic lymphohistiocytosis (HLH)===
*2015: Schram & Berliner. How I treat hemophagocytic lymphohistiocytosis in the adult patient EuroPMC
===Langerhans cell histiocytosis (LCH)===
*2015: Allen et al. How I treat Langerhans cell histiocytosis EuroPMC
=Classical hematology=
==Hemostasis and thrombosis==
*2023: Samuelson Bannow & Konkle. How I approach bleeding in hospitalized patients EuroPMC
*2021: Baker & O'Donnell. How I treat bleeding disorder of unknown cause EuroPMC
*2016: Martin & Key. How I treat patients with inherited bleeding disorders who need anticoagulant therapy EuroPMC
*2015: Pavord & Maybury. How I treat postpartum hemorrhage EuroPMC
*2014: Johansson et al. How I treat patients with massive hemorrhage EuroPMC
*2014: Levy & Goodnough. How I use fibrinogen replacement therapy in acquired bleeding EuroPMC
===Acquired thrombotic thrombocytopenic purpura (aTTP)===
*2022: Akwaa et al. How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge
*2020: Ferrari & Peyvandi. How I treat thrombotic thrombocytopenic purpura in pregnancy
*2015: Sayani & Abrams. How I treat refractory thrombotic thrombocytopenic purpura EuroPMC
===Antiphospholipid antibody syndrome (APS)===
*2024: Branch & Lim How I diagnose and treat antiphospholipid syndrome in pregnancy EuroPMC
*2021: Cohen & Isenberg. How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome EuroPMC
*2015: Ortel et al. How I treat catastrophic thrombotic syndromes EuroPMC
===Arterial thromboembolism (ATE)===
*2024: May & Moll. How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both? EuroPMC
*2020: May & Moll. How I treat unexplained arterial thrombosis EuroPMC
===Disseminated intravascular coagulation (DIC)===
*2018: Levi & Scully. How I treat disseminated intravascular coagulation EuroPMC
===Hemophilia===
*2020: Leebeek et al. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease
*2019: Young. How I treat children with haemophilia and inhibitors
*2015: Leissinger et al. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors EuroPMC
*2012: Mannucci & Mancuso. How we choose factor VIII to treat hemophilia EuroPMC
===Heparin-induced thrombocytopenia (HIT)===
*2016: Warkentin & Anderson. How I treat patients with a history of heparin-induced thrombocytopenia EuroPMC
===Hereditary hemorrhagic telangiectasia (HHT)===
*2024: Al-Samkari. How I treat bleeding in hereditary hemorrhagic telangiectasia EuroPMC
===Thrombotic microangiopathy (TMA)===
*2023: Doreille et al. How I treat thrombotic microangiopathy in the era of rapid genomics
*2021: Thomas & Scully. How I treat microangiopathic hemolytic anemia in patients with cancer
===Venous thromboembolism (VTE)===
*2024: Bhat et al. How I treat pediatric venous thromboembolism in the DOAC era EuroPMC
**2017: Young. How I treat pediatric venous thromboembolism EuroPMC
*2024: Leader et al. How I treat acute venous thromboembolism in patients with brain tumors EuroPMC
*2024: May & Moll. How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both? EuroPMC
*2023: Akpan & Hunt. How I approach the prevention and treatment of thrombotic complications in hospitalized patients EuroPMC
**2012: Dobromirski & Cohen. How I manage venous thromboembolism risk in hospitalized medical patients EuroPMC
*2022: Schmidt & Lee. How I treat and prevent venous thrombotic complications in patients with lymphoma
*2020: Klok & Huisman. How I assess and manage the risk of bleeding in patients treated for venous thromboembolism
*2020: Middeldorp & Ganzevoort. How I treat venous thromboembolism in pregnancy
*2020: Wang & Carrier. How I treat obese patients with oral anticoagulants
*2019: Pabinger & Thaler. How I treat patients with hereditary antithrombin deficiency
*2019: Chan & Eikelbloom. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism
*2019: Kraaijpoel & Carrier. How I treat cancer-associated venous thromboembolism
*2018: Rabinovich & Kahn. How I treat the postthrombotic syndrome EuroPMC
*2018: Shet & Wun. How I diagnose and treat venous thromboembolism in sickle cell disease
*2018: Vedantham & Sista. How I use catheter-directed interventional therapy to treat patients with venous thromboembolism EuroPMC
*2017: Schulman. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy EuroPMC
*2015: Kyrle. How I treat recurrent deep-vein thrombosis EuroPMC
*2015: O'Connell. How I treat incidental pulmonary embolism EuroPMC
*2014: Ageno et al. How I treat splanchnic vein thrombosis EuroPMC
*2014: Palareti. How I treat isolated distal deep vein thrombosis (IDDVT) EuroPMC
===von Willebrand disease (vWD)===
*2024: Poston & Kruse-Jarres How I treat von Willebrand disorders in older adults EuroPMC
*2020: Biguzzi et al. How I treat gastrointestinal bleeding in congenital and acquired von Willebrand disease
*2020: Leebeek et al. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease
*2019: Lavin & O'Donnell. How I treat low von Willebrand factor levels
*2018: Kruse-Jarres & Johnsen. How I treat type 2B von Willebrand disease EuroPMC
*2014: Tosetto & Castaman. How I treat type 2 variant forms of von Willebrand disease EuroPMC
*2011: Tiede et al. How I treat the acquired von Willebrand syndrome EuroPMC
==Cytopenias==
===Acquired pure red cell aplasia===
*2021: Gurnari & Maciejewski. How I manage acquired pure red cell aplasia in adults EuroPMC
===Anemia===
*2024: Oyedeji et al. How I treat anemia in older adults EuroPMC
*2023: Carson & Brittenham. How I treat anemia with red blood cell transfusion and iron EuroPMC
*2021: Gurnari & Maciejewski. How I manage acquired pure red cell aplasia in adults
*2020: Anand & Gupta. How I treat anemia in heart failure
*2020: Fishbane & Coyne. How I treat renal anemia
*2020: Gilreath & Rodgers. How I treat cancer-associated anemia
*2020: Shander et al. How I treat anemia in the perisurgical setting
*2016: Achebe & Gafter-Gvili. How I treat anemia in pregnancy: iron, cobalamin, and folate EuroPMC
*2014: Hershko & Camaschella. How I treat unexplained refractory iron deficiency anemia
===Aplastic anemia===
*2017: Bacigalupo. How I treat acquired aplastic anemia EuroPMC
===Autoimmune cytopenia===
*2022: Porpaczy & Jäger. How I manage autoimmune cytopenias in patients with lymphoid cancer EuroPMC
===Immune thrombocytopenia (ITP)===
*2021: Ghanima et al. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment
*2016: Cuker & Neunert. How I treat refractory immune thrombocytopenia EuroPMC
===Neutropenia & leukopenia===
*2014: Gibson & Berliner. How we evaluate and treat neutropenia in adults EuroPMC
===Thrombocytopenia and platelet dysfunction===
*2024: Foy et al. How I diagnose and treat thrombocytopenia in geriatric patients EuroPMC
*2024: Fogerty & Kuter How I treat thrombocytopenia in pregnancy EuroPMC
**2012: Gernsheimer et al. How I treat thrombocytopenia in pregnancy EuroPMC
*2023: Stanworth & Mumford. How I diagnose and treat neonatal thrombocytopenia EuroPMC
*2022: Stanworth & Shah. How I use platelet transfusions EuroPMC
*2022: Fiore et al. How I manage pregnancy in women with Glanzmann thrombasthenia
*2021: Kyrle & Eichinger. How I manage cyclic thrombocytopenia
*2016: Greinacher & Selleng. How I evaluate and treat thrombocytopenia in the intensive care unit patient EuroPMC
===WHIM syndrome===
*2017: Badolato et al. How I treat warts, hypogammaglobulinemia, infections, and myelokathexis syndrome EuroPMC
==Hemoglobinopathies==
===Beta thalassemia===
*2023: Saliba et al. How I treat non-transfusion-dependent β-thalassemia EuroPMC
*2018: Taher & Cappellini. How I manage medical complications of β-thalassemia in adults EuroPMC
===Sickle cell disease===
*2024: James & Strouse How I treat sickle cell disease in pregnancy EuroPMC
*2024: Sharma How I treat sickle cell disease with gene therapy EuroPMC
*2019: Stenger et al. How I treat sickle cell disease with hematopoietic cell transplantation
*2018: Pirenne & Yazdanbakhsh. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions EuroPMC
*2018: Shet & Wun. How I diagnose and treat venous thromboembolism in sickle cell disease
*2018: Thein & Howard. How I treat the older adult with sickle cell disease
*2015: Anele et al. How I treat priapism EuroPMC
*2015: Kassim et al. How I treat and manage strokes in sickle cell disease EuroPMC
*2014: Sharpe & Thein. How I treat renal complications in sickle cell disease EuroPMC
==Hemolytic disorders==
*2018: Machogu & Machado. How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders EuroPMC
*2017: Go et al. How I treat autoimmune hemolytic anemia EuroPMC
===Cold agglutinin disease (CAD)===
*2021: Berentsen. How I treat cold agglutinin disease
===Atypical hemolytic uremic syndrome (aHUS)===
*2023: Fakhouri et al. How I diagnose and treat atypical hemolytic uremic syndrome EuroPMC
*2014: Cataland & Wu. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome EuroPMC
===Paroxysmal nocturnal hemoglobinuria (PNH)===
*2021: Brodsky. How I treat paroxysmal nocturnal hemoglobinuria
*2009: Brodsky. How I treat paroxysmal nocturnal hemoglobinuria EuroPMC
===Warm autoimmune hemolytic anemia (WAIHA)===
*2021: Barcellini & Fattizzo. How I treat warm autoimmune hemolytic anemia
=Special considerations=
==Age-based recommendations==
The majority of How I Treat articles focus on "standard" adults; below, articles that focus on other age populations are concatenated.
===Neonates===
*2025: Bartram et al. How I treat infant acute lymphoblastic leukemia EuroPMC
*2023: Stanworth & Mumford How I diagnose and treat neonatal thrombocytopenia EuroPMC
*2018: Brown et al. How I treat infant leukemia EuroPMC
===Children===
*2025: Summers et al. How I treat ETP-ALL in children EuroPMC
*2025: Tran & Tasian. How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults EuroPMC
*2024: Bhat et al. How I treat pediatric venous thromboembolism in the DOAC era EuroPMC
**2017: Young. How I treat pediatric venous thromboembolism EuroPMC
*2023: Myers et al. How I use risk factors for success or failure of CD19 CAR T cells to guide management of children and AYA with B-cell ALL EuroPMC
*2023: Si Lim et al. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults EuroPMC
*2021: Rubnitz & Kaspers. How I treat pediatric acute myeloid leukemia EuroPMC
*2020: Hunger & Raetz. How I treat relapsed acute lymphoblastic leukemia in the pediatric population EuroPMC
*2020: Teachey & O'Connor How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children EuroPMC
*2019: Hijiya & Suttorp. How I treat chronic myeloid leukemia in children and adolescents EuroPMC
*2018: Gopal & Gross. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa EuroPMC
*2018: Locatelli & Strahm. How I treat myelodysplastic syndromes of childhood EuroPMC
*2012: Locatelli et al. How I treat relapsed childhood acute lymphoblastic leukemia EuroPMC
===Adolescents and young adults (AYA)===
*2025: Tran & Tasian. How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults EuroPMC
*2023: Si Lim et al. How I treat newly diagnosed and refractory T-cell acute lymphoblastic lymphoma in children and young adults EuroPMC
*2019: Hijiya & Suttorp. How I treat chronic myeloid leukemia in children and adolescents EuroPMC
*2019: Young. How I treat children with haemophilia and inhibitors
*2018: Gopal & Gross. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa EuroPMC
*2015: Curran & Stock. How I treat acute lymphoblastic leukemia in older adolescents and young adults EuroPMC
===Older adults/Geriatric hematology===
*2025: Gökbuget & Steffen. How I treat older patients with Ph/BCR-ABL-negative acute lymphoblastic leukemia EuroPMC
**2013: Gökbuget. How I treat older patients with ALL EuroPMC
*2025: Wallace et al. How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma EuroPMC
*2024: Facon et al. How I treat multiple myeloma in geriatric patients EuroPMC
**2010: Mehta et al. How I treat elderly patients with myeloma EuroPMC
*2024: Foy et al. How I diagnose and treat thrombocytopenia in geriatric patients EuroPMC
*2024: Oyedeji et al. How I treat anemia in older adults EuroPMC
*2024: Poston & Kruse-Jarres How I treat von Willebrand disorders in older adults EuroPMC
*2023: Lugtenburg & Mutsaers How I treat older patients with DLBCL in the frontline setting EuroPMC
*2019: Chan & Eikelbloom. How I manage anticoagulant therapy in older individuals with atrial fibrillation or venous thromboembolism
*2018: Thein & Howard. How I treat the older adult with sickle cell disease EuroPMC
*2014: Ossenkoppele & Löwenberg. How I treat the older patient with acute myeloid leukemia EuroPMC
**2000: Estey. How I treat older patients with AML EuroPMC
==Complications of treatment==
===Bleeding===
*2017: Boonyawat et al. How I treat heavy menstrual bleeding associated with anticoagulants EuroPMC
*2014: Schulman & Furie. How I treat poisoning with vitamin K antagonists EuroPMC
*2014: Siegal et al. How I treat target-specific oral anticoagulant-associated bleeding EuroPMC
===Cardiovascular complications===
*2022: Herrmann et al. How I treat cardiovascular complications in patients with lymphoid malignancies EuroPMC
===Immune effector cells toxicity management===
*2023: Gutierrez et al. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy EuroPMC
*2023: Jain et al. How I treat refractory CRS and ICANS after CAR T-cell therapy EuroPMC
*2023: Jain et al. How I treat cytopenias after CAR T-cell therapy EuroPMC
*2023: Santomasso et al. How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity EuroPMC
*2020: Hill & Seo How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
===Infectious complications===
*2023: Dadwal et al. How I prevent viral reactivation in high-risk patients EuroPMC
*2022: El Chaer et al. How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies EuroPMC
*2022: Law & Taplitz. How I manage infection risk and prevention in patients with lymphoid cancer EuroPMC
*2020: Hill & Seo. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies
*2016: El Chaer et al. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients EuroPMC
*2016: Waghmare et al. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation EuroPMC
*2014: Nucci & Anaissie. How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach EuroPMC
===Iron overload===
*2012: Hoffbrand et al. How I treat transfusional iron overload EuroPMC
*2025: Angelucci How I manage iron overload in the hematopoietic cell transplantation setting EuroPMC
*2025: Leitch & Buckstein How I treat iron overload in adult MDS EuroPMC
===Medication toxicities===
*2017: Delforge & Ludwig. How I manage the toxicities of myeloma drugs EuroPMC
===Neurologic medications===
*2022: Nayak & Batchelor. How I treat neurologic complications in patients with lymphoid cancer EuroPMC
==Genetic risk==
*2023: Hamilton et al. How I communicate with patients and families about germ line genetic information EuroPMC
*2016: University of Chicago Hematopoietic Malignancies Cancer Risk Team How I diagnose and manage individuals at risk for inherited myeloid malignancies EuroPMC
==Gynecologic considerations==
===Menstruation===
*2017: Boonyawat et al. How I treat heavy menstrual bleeding associated with anticoagulants EuroPMC
===Pregnancy===
*2024: Branch & Lim How I diagnose and treat antiphospholipid syndrome in pregnancy EuroPMC
*2024: Fogerty & Kuter How I treat thrombocytopenia in pregnancy EuroPMC
**2012: Gernsheimer et al. How I treat thrombocytopenia in pregnancy EuroPMC
*2024: James & Strouse How I treat sickle cell disease in pregnancy EuroPMC
*2024: Robinson et al. How I treat myeloproliferative neoplasms in pregnancy EuroPMC
*2022: Fiore et al. How I manage pregnancy in women with Glanzmann thrombasthenia
*2020: Dunleavy & McLintock. How I treat lymphoma in pregnancy
*2020: Ferrari & Peyvandi. How I treat thrombotic thrombocytopenic purpura in pregnancy
*2020: Leebeek et al. How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease
*2020: Middeldorp & Ganzevoort. How I treat venous thromboembolism in pregnancy
*2016: Achebe & Gafter-Gvili. How I treat anemia in pregnancy: iron, cobalamin, and folate EuroPMC
*2013: Milojkovic & Apperley. How I treat leukemia during pregnancy EuroPMC
===Postpartum period===
*2015: Pavord & Maybury. How I treat postpartum hemorrhage EuroPMC
==Hospitalization==
*2023: Akpan & Hunt. How I approach the prevention and treatment of thrombotic complications in hospitalized patients EuroPMC
*2023: Samuelson Bannow & Konkle. How I approach bleeding in hospitalized patients EuroPMC
*2023: Zon & Berliner. How I manage inpatient consultations for quantitative neutrophil abnormalities in adults EuroPMC
*2012: Dobromirski & Cohen. How I manage venous thromboembolism risk in hospitalized medical patients EuroPMC
==Regional considerations==
*2018: Gopal & Gross. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa EuroPMC
==Surgical considerations==
*2020: Shander et al. How I treat anemia in the perisurgical setting
*2012: Spyropoulos & Douketis. How I treat anticoagulated patients undergoing an elective procedure or surgery EuroPMC
==Transplantation==
===Allogeneic HSCT===
*2025: Angelucci. How I manage iron overload in the hematopoietic cell transplantation setting EuroPMC
*2025: Hamad. How I approach intersectionality in hematopoietic stem cell transplantation EuroPMC
*2024: Lai et al. How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients EuroPMC
*2024: Mina et al. How I reduce and treat posttransplant relapse of MDS EuroPMC
*2023: DeFilipp & Chen. How I treat with maintenance therapy after allogeneic HCT EuroPMC
*2021: Burns & Morris. How I use allogeneic HSCT for adults with inborn errors of immunity EuroPMC
*2020: Puerta-Alcalde et al. How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease EuroPMC
*2019: McCurdy & Luznik. How we perform haploidentical stem cell transplantation with posttransplant cyclophosphamide EuroPMC
*2018: Gribben. How and when I do allogeneic transplant in CLL EuroPMC
*2017: Alvarnas et al. How I treat patients with HIV-related hematological malignancies using hematopoietic cell transplantation EuroPMC
*2017: Williams. How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation EuroPMC
*2016: El Chaer et al. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients EuroPMC
*2012: Wingard et al. How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation EuroPMC
===Autologous HSCT===
*2014: Gertz & Dingli. How we manage autologous stem cell transplantation for patients with multiple myeloma EuroPMC
===Graft versus host disease (GVHD)===
*2023: Cooper & Abkowitz. How I diagnose and treat acute graft-versus-host disease after solid organ transplantation
*2023: Rimando et al. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond
*2020: Martin. How I treat steroid-refractory acute graft-versus-host disease EuroPMC
*2019: Sarantopoulos et al. How I treat refractory chronic graft-versus-host disease EuroPMC
*2016: McDonald. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver EuroPMC
*2014: Flowers & Martin. How we treat chronic graft-versus-host disease EuroPMC
*2012: Treister et al. How we treat oral chronic graft-versus-host disease EuroPMC
*2007: Deeg. How I treat refractory acute GVHD EuroPMC
=Miscellaneous=
==Acute respiratory failure==
*2024: Azoulay et al. How I manage acute respiratory failure in patients with hematological malignancies EuroPMC
==Atrial fibrillation==
*2016: Steinberg. How I use anticoagulation in atrial fibrillation EuroPMC
==Cryoglobulinemia==
*2016: Muchtar et al. How I treat cryoglobulinemia EuroPMC
Category:Hematology reference pages
Category:Evidence-based oncology
==Immunodeficiency==
===Common variable immune deficiency (CVID)===
*2010: Cunningham-Rundles. How I treat common variable immune deficiency EuroPMC
===Severe combined immunodeficiency (SCID)===
*2013: Gaspar et al. How I treat severe combined immunodeficiency EuroPMC
==Priapism==
*2015: Anele et al. How I treat priapism EuroPMC
==Protoporphyria==
*2023: Karp Leaf & Dickey. How I treat erythropoietic protoporphyria and X-linked protoporphyria EuroPMC
==T-cell chronic active Epstein-Barr virus disease (CAEBV)==
*2018: Bollard & Cohen. How I treat T-cell chronic active Epstein-Barr virus disease EuroPMC